Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

AIM: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. PATIENTS & METHODS: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R)...

Descripción completa

Detalles Bibliográficos
Autores principales: Thongprasert, Sumitra, Geater, Sarayut L, Clement, Dana, Abdelaziz, Amr, Reyes-Igama, Jasmin, Jovanovic, Dragana, Alexandru, Aurelia, Schenker, Michael, Sriuranpong, Virote, Serwatowski, Piotr, Suresh, Sheethal, Cseh, Agnieszka, Gaafar, Rabab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891940/
https://www.ncbi.nlm.nih.gov/pubmed/31807143
http://dx.doi.org/10.2217/lmt-2019-0004
Descripción
Sumario:AIM: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. PATIENTS & METHODS: In this open-label, single-arm Phase IV study, patients with EGFRm+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response. RESULTS: 60 patients received afatinib for a median duration of 11.5 months. 50% of patients had a confirmed objective response, of median duration 13.8 months. Median progression-free survival was 10.9 months. The most common treatment-related adverse events were diarrhea (72%), rash (28%) and paronychia (23%). CONCLUSION: Our data support the use of afatinib (40 mg/day) as an effective and well-tolerated second-line treatment in EGFRm+ NSCLC.

Ejemplares similares